Biodegradable Graphene Sensors Made From Agripapers
Researchers at XYZ University have unveiled a new class of biodegradable sensors that combine graphene with agripaper—a paper made from agricultural residues. The devices demonstrate up to 95% of the sensitivity of conventional graphene sensors while fully decomposing in compost within a month. Production uses low‑temperature, water‑based processes, slashing energy use and eliminating hazardous chemicals. The breakthrough positions agripaper‑based graphene as a viable alternative for disposable IoT and medical diagnostics.
Sperm DNA Fragmentation: Impact on Mammalian Reproduction
Recent studies reveal that sperm DNA fragmentation (SDF) significantly impairs mammalian reproductive outcomes, lowering fertilization rates and embryo quality. Researchers attribute elevated SDF to oxidative stress, environmental toxins, and advancing male age, prompting a surge in diagnostic testing. Clinical trials...
Round Three of IRA Negotiations Is Expected to Be ‘Manageable’ for Pharma
Analysts say the third round of Medicare drug‑price negotiations under the Inflation Reduction Act will be largely manageable for large pharmaceutical firms. The round focuses on a limited set of high‑cost specialty medicines, with negotiations slated to begin in 2025....
Nautilus, Weill Cornell Team Up to Apply Single Molecule Proteomics Tech to Parkinson’s
Nautilus and Weill Cornell Medicine‑Qatar have secured $1.6 million from the Michael J. Fox Foundation to develop a single‑molecule proteomics assay for alpha‑synuclein proteoforms in Parkinson’s disease. The collaboration merges Hilal Lashuel’s expertise in alpha‑synuclein post‑translational modifications with Nautilus’s Iterative Mapping...
Gut Bacteria Lysogeny Alters Genome Profiles Significantly
Researchers led by K. Pick and T.L. Raivio applied transcriptomic profiling to a lysogenic Escherichia coli strain cultured in simulated intestinal fluid. Integrated bacteriophage DNA caused extensive changes in both core and accessory gene expression, notably affecting virulence and metabolic...
Unprecedented 3D Views of Sensory Cells Accelerate Hearing Research
University of California San Diego researchers unveiled Vision Analysis StereoCilia (VASCilia), an AI‑driven tool that creates high‑resolution 3D visualizations of cochlear hair‑cell stereocilia. By applying five deep‑learning models, VASCilia accelerates image analysis by roughly 50‑fold compared with manual methods. The...
PlasmoBridge Chip Enables Ultrasensitive and Rapid Monitoring of Methotrexate
Researchers at the Chinese Academy of Sciences unveiled PlasmoBridge, a dual‑functional sensor chip that uses aptamer‑linked silver nanoparticles to generate plasmonic hotspots for methotrexate detection. The platform achieves a limit of detection of 4.64 × 10⁻⁸ M and, with a convolutional neural network,...
Complete Human Genome Tandem Repeat Catalog Released
An international consortium has released the first comprehensive catalog of tandem repeats across the entire human genome, covering more than one million loci. The database provides detailed repeat length distributions, population allele frequencies from over 100,000 sequenced genomes, and functional...
FDA Asks Court to Pause Louisiana's Abortion Pill Fight
The U.S. Justice Department, representing the Trump administration, has petitioned a federal court to suspend a Louisiana lawsuit challenging the FDA’s approval of the abortion medication mifepristone. The request comes as the FDA conducts a comprehensive safety and efficacy review...
Rare Disease Therapies: From Niche Experiment to Strategic Growth Engine
Rare‑disease therapies have shifted from a niche experiment to a core growth engine for biopharma, driven by the 1983 Orphan Drug Act and subsequent incentives. Smaller, adaptive trials and surrogate endpoints have lowered development costs, with orphan drugs averaging about...
Halozyme Diversifies in Drug Delivery with Surf Bio Buy
Halozyme Therapeutics has bolstered its drug‑delivery portfolio by acquiring Surf Bio for a $300 million upfront payment, adding the ultrahigh‑concentration Snapshot platform. The deal follows a recent $750 million purchase of Elektrofi, giving Halozyme three complementary technologies for subcutaneous administration. Snapshot enables...
Lonza Still Intends to Sell Its Capsules and Health Ingredients Business
Swiss CDMO Lonza reaffirmed its intention to sell its capsules and health ingredients division. The transaction, first announced more than a year ago, has not yet been finalized. Lonza cited ongoing negotiations and market conditions as reasons for the delay....
Separase’s Key Role in Nuclear Lamin Regulation
Researchers have uncovered that separase, the protease known for triggering sister‑chromatid separation, directly cleaves nuclear lamins during mitotic entry. The study demonstrates that separase-mediated lamin A/C cleavage is essential for nuclear envelope breakdown and proper chromosome segregation. Using CRISPR‑engineered human...
Capturing the Moment of Organelle Handoff Inside Living Cells
Researchers have, for the first time, directly visualized autophagosomes moving from the endoplasmic reticulum (ER) onto microtubule tracks inside living cells. By combining interferometric scattering microscopy with fluorescence labeling in a custom DySLIM platform, they captured the handoff event with...
How a Government Shutdown Causes FDA Inspection Bottlenecks and Backlogs
A looming U.S. government shutdown could cripple FDA operational capacity, turning routine inspections into a bottleneck and creating a sizable backlog of pending reviews. While user‑fee‑funded core reviews may continue, the loss of predictability hampers agency responsiveness and administrative processing....
Long-Term Prognosis for Older Classical Hodgkin Lymphoma Patients
A recent multi‑center analysis examined long‑term outcomes for patients over 60 with classical Hodgkin lymphoma (cHL). Using modern PET‑adapted regimens, five‑year overall survival rose to roughly 70%, though treatment‑related toxicity remains a key challenge. The study highlighted the benefit of...
Exercise-Derived Vesicles: A Breakthrough in Cancer Therapy
Researchers led by Silvestri et al. have shown that extracellular vesicles released during physical exercise carry proteins, lipids and RNA that can influence tumor biology. The study demonstrates that these exercise‑derived EVs can boost immune recognition of cancer cells and...
Key Factors in Cardiovascular Care Delivery
A new BMC Health Services Research study by Durmuş and Akbolat maps the expectations of cardiovascular patients across clinical, interpersonal, environmental, digital, and demographic dimensions. The research reveals that empathy, provider competence, and a welcoming care environment are as critical...
Advanced TadA Editors Enable Precise Disease Variant Modeling
Researchers have unveiled next‑generation TadA‑based adenine base editors that achieve near‑perfect A‑to‑G conversion at disease‑relevant loci. The editors demonstrate editing efficiencies up to 95% with off‑target rates below 0.1%, and have been used to generate more than 30 pathogenic point...
Teva CEO Says It Has Successfully Transitioned Into a Biopharma Company
Teva Pharmaceutical Industries announced that its latest earnings demonstrate a completed shift from a pure‑play generics manufacturer to a biopharma‑focused enterprise. The CEO highlighted that revenue from specialty and branded products now exceeds traditional generic sales, confirming the strategic pivot....
Dual-Channel High-Speed Photoacoustic Microscopy Revolutionizes Wide Imaging
Researchers unveiled a dual‑channel high‑speed photoacoustic microscopy system that captures wide‑field images up to 10 mm in a single shot, effectively doubling acquisition speed compared with single‑channel setups. The platform synchronizes two laser beams and parallel acoustic detectors, delivering sub‑micron resolution...
Glucose Monitoring with Novel Reusable Sensor
Hamilton has launched the GlucoSense reusable sensor, a compact inline probe that provides real‑time glucose monitoring for mammalian cell cultures. The device uses infrared spectrometry and integrates directly with its transmitter, eliminating the need for an external spectrometer or lengthy...
Permittivity Provides an In-Line Cell Health Early-Warning System
Merck scientists demonstrated that dielectric spectroscopy, measured as permittivity, can serve as an in‑line early‑warning system for apoptosis in CHO cell cultures. By analyzing Cole‑Cole model parameters—critical frequency (fc) and delta epsilon (Δε)—they captured stress‑induced shifts before conventional viability assays...
PH Denaturation of dsRNA for mRNA Purification
Scientists at Sartorius BIA Separations and Johannes Gutenberg University have introduced a low‑pH denaturation step that melts double‑stranded RNA (dsRNA) impurities in mRNA streams within seconds. By adjusting the pH to 3.5 or lower, dsRNA levels fall below 0.1% while...
Rethinking Vaccine Production Platforms for Future Pandemics
New analysis highlights yeast-based protein expression as a promising vaccine platform for future pandemics. While mRNA and viral vector technologies enabled rapid COVID‑19 vaccine rollout, their high cost, manufacturing complexity, and cold‑chain requirements limited access in low‑income regions. Yeast systems...
LINC00857 Drives Pancreatic Cancer via miR-130b/RHOA
Researchers have identified the long non‑coding RNA LINC00857 as a driver of pancreatic ductal adenocarcinoma through a miR‑130b/RHOA signaling axis. The study shows LINC00857 is overexpressed in patient tumors and functions as a molecular sponge, sequestering miR‑130b and thereby upregulating...
SiRNA Transport Drives Pollen Development Functions
Researchers have uncovered that small interfering RNA (siRNA) molecules are actively transported from the vegetative nucleus to sperm cells during pollen development, a process essential for proper gene silencing. The study, conducted in Arabidopsis thaliana, shows that disrupting siRNA transport...
Function of Cell Surface glycoRNAs Identified
Researchers led by Ryan Flynn have identified the cellular pathway that places glycoRNAs on the cell surface and demonstrated that these RNA‑glycan hybrids bind and inhibit VEGF‑A signaling. Genetic screens linked heparan sulfate to glycoRNA presentation, and loss of glycoRNAs...
Malabsorption Detected by Glowing Bacterial Biosensors in Mice
University of British Columbia researchers engineered the native gut bacterium Bacteroides thetaiotaomicron to act as a continuous, noninvasive biosensor that glows brightly under normal conditions and dims when osmotic stress indicates malabsorption. Published in Cell, the study demonstrated in mice...
AI Tool AlphaGenome Predicts How One Typo Can Change a Genetic Story
Google DeepMind unveiled AlphaGenome, a deep‑learning model that can process one million DNA bases in a single context, doubling the reach of its predecessor Borzoi. The system predicts eleven genomic functions at single‑base resolution, delivering a 14.7% improvement in gene‑activity...
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
The FDA placed a clinical hold on REGENXBIO’s RGX‑111 and RGX‑121 after a tumor was found in a five‑year‑old patient potentially linked to the AAV vector. The hold jeopardizes REGENXBIO’s Feb. 8, 2026 PDUFA deadline for its Hunter syndrome gene therapy. Denali...
HHS Seeks to Protect Drugmakers From Anti-Kickback Laws Ahead of TrumpRx Launch
The U.S. Department of Health and Human Services announced a draft rule that would create a safe‑harbor exemption for drug manufacturers participating in the upcoming TrumpRx platform. The proposal seeks to shield companies from the federal anti‑kickback statute when they...
Hengrui Blazes Trail as Chinese Drugmakers Aspire to Go Multinational
Jiangsu Hengrui Pharmaceuticals has surged into the global top‑25 biopharma companies by market value, marking a dramatic shift from its previously low international profile. The Chinese firm leveraged a pipeline of innovative oncology and immunology drugs, securing multiple foreign regulatory...
Halozyme Buys Drug Delivery Biotech Surf Bio; Sanofi Backs Sensorion
Halozyme Therapeutics announced a $300 million upfront acquisition of drug‑delivery biotech Surf Bio, adding its PEGylated enzyme platform to Halozyme’s existing portfolio. The deal is expected to broaden Halozyme’s subcutaneous biologics pipeline and accelerate commercialization of next‑generation delivery technologies. Concurrently, Sanofi...
NK Cell Insights Into Ankylosing Spondylitis Severity
Recent immunological research reveals that natural killer (NK) cells play a pivotal role in the severity of ankylosing spondylitis (AS). The study found a proportional increase in peripheral NK cell frequency and activation markers correlating with higher Bath Ankylosing Spondylitis...
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
The FDA approved Johnson & Johnson’s Darzalex Faspro as part of a four‑drug regimen for newly diagnosed multiple myeloma patients who cannot undergo stem cell transplantation. This is the drug’s twelfth overall and fifth frontline indication. Phase III CEPHEUS data showed 52.3%...
IXCells and Rosebud Biosciences Partner on Organoid-Based Rare Disease Models
iXCells Biotechnologies is integrating Rosebud Biosciences’ AI‑driven organoid platform with its iPSC‑based iPSCore system to deliver scalable, three‑dimensional human tissue models. The partnership combines iXCells’ modular stem‑cell production with Rosebud’s reproducible organoid generation and characterization capabilities. Together they aim to...
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Advanced Therapies Week 2026 in San Diego will spotlight the accelerating yet turbulent landscape of cell and gene therapies. New FDA guidance, including the plausible‑mechanism pathway, promises faster approvals, while recent U.S. cuts to mRNA projects and a wave of...
CD81’s Role in Immune Response and Myeloma Prognosis
Recent studies identify CD81, a tetraspanin protein, as a key regulator of immune cell function in multiple myeloma. Patients exhibit reduced CD81 on T cells, impairing anti‑tumor responses, while higher overall CD81 levels correlate with improved survival and therapy response....
Cardiff Craters Amid Executive Exits, Mixed Mid-Stage Data
Cardiff Oncology announced the departure of its CEO and CFO while releasing mixed Phase II data for its PLK1 inhibitor onvansertib. In the CRDF‑004 trial, the 30 mg dose combined with FOLFIRI + bevacizumab achieved a 72.2% objective response rate and a 62% reduction...
Boehringer Drug Scores in Rare Kidney Disease FSGS
Boehringer Ingelheim’s TRPC6 inhibitor apecotrep, originally a COVID‑19 candidate, achieved a 40% reduction in proteinuria versus placebo in a phase 2 trial for primary focal segmental glomerulosclerosis (FSGS). The study, published in The Lancet, provides the first efficacy signal for a...
Biopharma Sentiment Index | Q1 2026
The Biopharma Sentiment Index (BPSI) jumped to 90 in Q1 2026, up from 78 in the prior quarter, marking the strongest sentiment shift in four years. All ten core measures improved, driven chiefly by a surge in dealmaking and better access...
Laser-Activated Nanodroplets Enable Photo-Activated Ultrasound Imaging
Researchers introduced photo‑activated ultrasound localization imaging (PAULI), using laser‑activated nanodroplets that vaporize into microbubbles for ultrasound detection. The method delivers micrometer‑scale spatial resolution and high contrast‑to‑noise ratios, surpassing traditional ultrasound. Activation is tunable via laser wavelength and pulse settings, allowing...
Hydroxychloroquine Fails to Improve COVID-19 Blood Biomarkers
A recent clinical trial found that hydroxychloroquine does not improve key blood biomarkers in COVID-19 patients. The study measured inflammatory markers, cytokine levels, and viral load among hospitalized individuals with moderate disease severity. No statistically significant changes were observed compared...
Reduced Body Segmentation in Skeleton Shrimp Revealed
Researchers led by Y. Otomo, R. Kimbara and K. Oguchi have documented a pronounced reduction in body segmentation of the skeleton shrimp *Caprella scaura*. By dissecting internal musculature and skeletal structures, the team demonstrated that this morphological simplification improves flexibility and maneuverability in...
Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More
Roche announced that its GLP‑1/GIP candidate CT‑388 achieved a 22.5% average weight loss in a Phase II study and will launch a Phase III trial early this year, pairing the drug with a Zealand Pharma therapy to curb gastrointestinal side effects. Baseline...
Lilly, Seamless Ink Up-to-$1.12B Hearing Loss Collaboration
Eli Lilly has signed a global research and licensing deal with German gene‑editing startup Seamless Therapeutics to develop hearing‑loss treatments using Seamless’s programmable recombinase platform. The agreement grants Lilly exclusive rights to engineered recombinases that can insert large DNA fragments...
Lilly Partners with Recombinase-Based Gene Editing Startup Seamless Therapeutics
Eli Lilly has entered a partnership with Seamless Therapeutics, a startup pioneering recombinase‑based gene editing. The collaboration will combine Lilly’s drug development platform with Seamless’s proprietary recombinase enzymes to create precise, permanent DNA modifications for therapeutic applications. Under the agreement,...
Boehringer Ingelheim Takes Rare Kidney Disease Drug to Phase 3 Despite Puzzling Mid-Stage Data
Boehringer Ingelheim announced that its experimental oral therapy for a rare kidney disorder will advance to a pivotal Phase 3 trial. The decision follows a Phase 2 study that demonstrated modest improvements in glomerular filtration rate but produced puzzling efficacy signals across...
CMS's Medicare Price Negotiations Start Round Three
The Centers for Medicare & Medicaid Services released the third round of Medicare drug price negotiations, naming 15 drugs that will face mandatory discounts starting in 2028. The list, which adds Eli Lilly’s GLP‑1 therapy Trulicity and several physician‑administered products such...
